
1. eur j gastroenterol hepatol. 2004 nov;16(11):1219-27.

histological response patients treated interferon plus ribavirin for
hepatitis c virus-related severe fibrosis.

abergel a(1), darcha c, chevallier m, ughetto s, henquell c, pol s, de ledinghen 
v, canva v, bronowicki jp, tran a, martineau n, lafeuille h, dechelotte p,
bommelaer g, bonny c; french multicentre study group.

author information: 
(1)services d'hépato-gastroentérologie, hôtel-dieu, clermont-ferrand, france.
aabergel@chu-clermontferrand.fr

background: studies viral hepatitis c suggested fibrosis can
regress, least patients sustained virological response. recent study
suggested cirrhosis reversible sustained non-virological
responders.
aim: study fibrosis progression rate cirrhosis reversion patients
treated severe fibrosis interferon interferon + ribavirin.
patients methods: ninety-nine patients treated interferon +
ribavirin 64 interferon. metavir fibrosis score the
semiquantitative fibrosis score (sfs) used assess fibrosis.
results: sustained responders, fibrosis progression rate decreased 0.26
metavir unit (interquartile range: 0.19-0.34) -0.67 (-0.67 0) (p < 0.0001) 
and 0.81 sfs unit (0.48-1.13) -1.33 (-3.67 0) (p < 0.0001). in
non-responders, fibrosis progression rate decreased 0.25 metavir unit
(0.17-0.33) treatment 0 (0-0) treatment (p = 0.002) from
0.63 sfs unit (0.49-1.12) 0 (-2.67-1.33) (p = 0.18). six 18 (33%)
sustained virological responders four 43 (9%) non-responders regressed
from cirrhosis (f4) severe fibrosis (f3) (p = 0.058). patient with
cirrhosis decrease metavir fibrosis score 2 points.
conclusion: interferon slow fibrosis progression sustained virological
responders severe fibrosis. patients non-virological response 
treated 12 months fibrosis progression rate nil, meaning only
fibrosis stabilization could obtained patients. then, longer
treatment duration (3-4 years) could evaluated non-virological responders.

doi: 10.1097/00042737-200411000-00022 
pmid: 15489585  [indexed medline]

